CombinatoRx Announces Discovery of Novel Synergistic Combination Leads for Glioblastoma; Data presented at AACR.CAMBRIDGE, Mass. -- CombinatoRx, Incorporated (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : CRXX) today announced the presentation of in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. data on novel combination drug candidates for glioblastoma multiforme glioblastoma mul·ti·for·me n. A virulent brain cancer that is usually fatal. (GBM GBM 1 Glioblastoma multiforme, see there 2. Glomerular basement membrane ) at the 97th Annual Meeting of the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational in Washington, D.C. The discovery of these novel synergistic combinations for GBM through the CombinatoRx proprietary combination High Throughput Screening (cHTS(TM)) drug discovery technology represents the successful completion of the collaboration with Accelerate Brain Cancer Cure Accelerate Brain Cancer Cure is a U.S.-based nonprofit organization with the mission to accelerate a cure for brain cancer by increasing the number of potential therapies and moving them rapidly into the clinic for patients. (ABC ABC in full American Broadcasting Co. Major U.S. television network. It began when the expanding national radio network NBC split into the separate Red and Blue networks in 1928. 2), a non-profit foundation dedicated to accelerating therapies leading to a cure for brain cancer. The sponsored research leveraged the CombinatoRx cHTS(TM) drug discovery technology with the goal of discovering novel drug combinations that hit multiple therapeutic targets relevant to the treatment of glioblastoma multiforme, a deadly form of brain cancer. The cHTS platform allowed CombinatoRx to discover synergistic activities of drug combinations acting on a network of molecular pathways. In a poster entitled "Systematic Discovery of Novel Multi-Target Therapies for Glioblastoma Multiforme" Margaret S. Lee, Ph.D., Executive Director, Therapeutic Area Research, of CombinatoRx, presented data from the cHTS program in a cellular model of GBM provided by Duke University. The study identified multiple synergistic combinations of approved cancer and non-cancer drugs. "These data, presented by Dr. Lee, further demonstrate the capability of the CombinatoRx cHTS discovery technology to rapidly identify novel synergistic combinations in serious diseases such as GBM," commented Alexis Borisy, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CombinatoRx. "In addition, we are pleased to have quickly and successfully delivered combinations that met the parameters specified in the agreement with our collaborator, ABC2. We look forward to the potential development of any product candidates that may result from this work, where CombinatoRx would retain the commercial rights to any drugs arising from this collaboration." The following information will be presented at AACR AACR American Association for Cancer Research AACR Anglo-American Cataloging Rules AACR Australasian Association of Cancer Registries AACR African Armed Conflicts Resolved on behalf of CombinatoRx: --Poster 1107, Discovering Multi-Target Modulators of Cancer Networks using High Throughput Combination Screening, Adrian Heilbut, et.al., Sunday, April 2, 2006, 1-5 PM --Poster 1357, Systematic Discovery of Novel Multi-Target Therapies for Glioblastoma Multiforme, Margaret S. Lee, et.al., Sunday, April 2, 2006, 1-5 PM. --Presentation, Forum on Combinations of Targeted Agents, M. James Nichols, Monday, April 3, 2006, 12:30-2:00PM --Poster 3096 In Vitro Characterization of the Human Biotransformation biotransformation /bio·trans·for·ma·tion/ (-trans?for-ma´shun) the series of chemical alterations of a compound (e.g., a drug) occurring within the body, as by enzymatic activity. Pathways of CRx-026, a Novel Syncretic syn·cre·tism n. 1. Reconciliation or fusion of differing systems of belief, as in philosophy or religion, especially when success is partial or the result is heterogeneous. 2. Anti-Cancer Drug Candidate, Camille Granvil, et.al., Monday, April 3, 2006, 1PM About CombinatoRx CombinatoRx, Incorporated is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immunoinflammatory disease, oncology, metabolic disease metabolic disease, n a disorder that causes dysfunction of the metabolic action of the body, resulting in loss of control of homeostasis. paraneoplastic syndrome , neurodegenerative disease, and infectious disease. We are currently developing a portfolio of 6 product candidates targeting multiple diseases which were discovered by applying our proprietary screening technology. For further information, please visit the CombinatoRx website at www.combinatorx.com. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995 concerning CombinatoRx, its plans for its product candidates, its collaboration with ABC2 and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the Company's drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional funding for its research and development and those other risks that can be found in the "Risk Factors" section of CombinatoRx's Annual Report Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. No forward-looking statement can be guaranteed and actual results may differ materially from those CombinatoRx projects. In addition, the forward-looking statements included in this press release represent CombinatoRx's views as of the date of this release. CombinatoRx anticipates that subsequent events and developments will cause its views to change. However, while CombinatoRx may elect to update these forward-looking statements at some point in the future, CombinatoRx specifically disclaims any obligation to do so, except as required by applicable law. These forward-looking statements should not be relied upon as representing CombinatoRx's views as of any date subsequent to the date of this release. (c) 2006 CombinatoRx, Incorporated. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion